Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Climb Bio, Inc. has 6 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Climb Bio, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Climb Bio, Inc.. Customers appear here when Climb Bio, Inc. names them, or when a company names Climb Bio, Inc. as a supplier in its own annual report.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Under the Asset Purchase Agreement, with respect to any "Product" (as such term is defined in the Asset Purchase Agreement), we are obligated to (i) make total payments of up to $157.5 million to Acelyrin upon the achievement of various development, regulatory and commercial milestones, (ii) pay royalties in the single-digit percentages, subject to specified reductions, to Acelyrin on worldwide net sales in a given calendar year, and (iii) make non-refundable and non-creditable payments to Acelyrin on sublicense income with rates ranging from the low single digit to mid teen percent depending on the stage of development of the most advanced Product at the time of such sublicense.”
FILING10-K0001193125-26-092546cik 0001768446
“For example, under the license agreement with CRH, CRH is responsible for prosecuting and maintaining intellectual property protection for budoprutug in consultation with us.”
FILING10-K0001193125-26-092546cik 0001768446
“In addition, we rely on Mabworks, a Chinese corporation, pursuant to the Mabworks Agreement, to conduct nonclinical studies of CLYM116 and to provide clinical supply of CLYM116 for these studies.”
FILING10-K0001193125-26-092546cik 0001768446
“In March 2025, we entered into an Equity Distribution Agreement (the Distribution Agreement) with Oppenheimer & Co. Inc., as agent (Oppenheimer), pursuant to which we may offer and sell shares of our common stock from time to time through Oppenheimer having an aggregate offering price of up to $22.4 million in an at the market offering.”
FILING10-K0001193125-26-092546cik 0001768446
“The ProBioGen Agreement granted us a non-exclusive license under certain know-how, patents and materials, to use cell lines in which ProBioGen's proprietary technology is applied, to research, develop, manufacture, use, sell, offer to sell, import or export budoprutug.”
FILING10-K0001193125-26-092546cik 0001768446
“We currently rely on certain foreign or foreign-owned third-party vendors, including WuXi and its affiliates, to manufacture certain materials used in the development of our product candidates or to provide services in connection with such development activities.”
FILING10-K0001193125-26-092546cik 0001768446
Watchlist prices, news filtered to it, and its next report on your desk.
CLYM (Climb Bio, Inc.) has 6 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Climb Bio, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 13.90 · gapped above the open, then crossed back over prior close. High/low 14.90 at 7:15 am ET, 13.42 at 1:30 pm ET.